Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $241.37M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.10M
Average 0.12M
Returns on capital
Profound Medical Corp. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.6%
avg -71.7%
ROIC
-22.7%
avg -53.8%
ROA
-22.4%
avg -48.6%
Analysis
ROA is currently the strongest return metric at -22.4% versus its period average of -48.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Arun Swarup Menawat | Chairman of the Board & Chief Executive Officer | CAD 998.59K | 71 | 587.09K | 1.94% |
Mathieu Burtnyk | Chief Technology Officer | CAD 479.84K | 44 | — | — |
Richard R. Fabian | President | CAD 479.84K | 59 | — | — |
Thomas Tamberrino | Chief Commercial Officer | CAD 382.2K | 46 | — | — |
Matthew Sobczyk | Interim Chief Financial Officer | — | 42 | — | — |
Stephen Kilmer | Investor Relations | — | — | — | — |
Levant Tinaz | Software Developer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 16, 2025.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +34.8% | +53.4% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +34.8% over three years. Forward estimates point to Revenue at +53.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Profound Medical Corp. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about PROF's management, answered from reported figures.
Who manages PROF?
Profound Medical Corp. (PROF) lists 7 active executives. The top listed executive is Arun Swarup Menawat, Chairman of the Board & Chief Executive Officer.
Are PROF insiders buying or selling?
Recent insider activity shows net buying of $100,150.69.
Continue the stock analysis
Jump to another research area for this company.